Peter Loftus
@loftus.bsky.social
Reporter covering drug companies, medical-device companies for The Wall Street Journal. Author of The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World
Sign of the times: telehealth firm's ad for weight-loss drugs to run during Super Bowl (by my colleague Katie Deighton): www.wsj.com/articles/him...
Hims & Hers to Advertise Weight-Loss Shots at the Super Bowl
Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced injectables.
www.wsj.com
January 28, 2025 at 3:31 PM
Sign of the times: telehealth firm's ad for weight-loss drugs to run during Super Bowl (by my colleague Katie Deighton): www.wsj.com/articles/him...
Reposted by Peter Loftus
Breaking: Ozempic and Wegovy are among 15 drugs up for a new round of price negotiations by Medicare
Ozempic Among the Next Drugs Up for Medicare Price Negotiations
List of drugs account for $41 billion in annual Medicare spending, the Biden administration said.
www.wsj.com
January 17, 2025 at 1:24 PM
Breaking: Ozempic and Wegovy are among 15 drugs up for a new round of price negotiations by Medicare
Reposted by Peter Loftus
JPMorgan is hosting its first major healthcare gathering since the death of UnitedHealthcare’s CEO Brian Thompson and security around industry leaders will be heavy
JPMorgan Hosts First Major Healthcare Gathering Since Death of UnitedHealthcare’s CEO
Industry leaders from more than 500 companies scheduled to give investor presentations will see heightened security surrounding the conference and related events. Many will have personal bodyguards.
www.wsj.com
January 13, 2025 at 2:41 PM
JPMorgan is hosting its first major healthcare gathering since the death of UnitedHealthcare’s CEO Brian Thompson and security around industry leaders will be heavy
Got news tips for The Wall Street Journal? Here are some secure ways to send tips or documents, anonymously or otherwise: www.wsj.com/tips
WSJ Tips
www.wsj.com
January 13, 2025 at 6:57 PM
Got news tips for The Wall Street Journal? Here are some secure ways to send tips or documents, anonymously or otherwise: www.wsj.com/tips
Will Medicare and Medicaid broadly cover anti-obesity meds like Wegovy? Outgoing Biden administration proposes it, up to incoming Trump admin to keep or scrap it. W/ @lizessleywhyte.bsky.social : www.wsj.com/health/healt...
White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs
More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.
www.wsj.com
November 26, 2024 at 4:49 PM
Will Medicare and Medicaid broadly cover anti-obesity meds like Wegovy? Outgoing Biden administration proposes it, up to incoming Trump admin to keep or scrap it. W/ @lizessleywhyte.bsky.social : www.wsj.com/health/healt...
The tried-and-true pharma marketing methods--TV ads, sales reps, etc.--only go so far when it comes to weight loss drugs. That's why Lilly and Novo are sending reps to employers, to get more of them to cover the drugs. It's not an easy sell, because of the high cost: www.wsj.com/health/pharm...
Makers of Weight-Loss Drugs Want Your Employer to Pay for Them
Eli Lilly, Novo Nordisk reps get facetime with employers in hopes they’ll cover their drugs
www.wsj.com
November 19, 2024 at 2:03 PM
The tried-and-true pharma marketing methods--TV ads, sales reps, etc.--only go so far when it comes to weight loss drugs. That's why Lilly and Novo are sending reps to employers, to get more of them to cover the drugs. It's not an easy sell, because of the high cost: www.wsj.com/health/pharm...
I wrote about the increasing use of an unusual treatment for difficult depression, J&J's Spravato, a cousin of ketamine: www.wsj.com/health/healt...
www.wsj.com
October 21, 2024 at 5:35 PM
I wrote about the increasing use of an unusual treatment for difficult depression, J&J's Spravato, a cousin of ketamine: www.wsj.com/health/healt...
Novo Nordisk's planned purchase of Catalent's manufacturing plants underscores the mismatch between demand and supply of popular new weight loss drugs: www.wsj.com/business/dea...
February 8, 2024 at 3:55 PM
Novo Nordisk's planned purchase of Catalent's manufacturing plants underscores the mismatch between demand and supply of popular new weight loss drugs: www.wsj.com/business/dea...